Clinical Trials for Pancreas Cancer

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults and children with biopsy-proven EBV-positive PTLD after solid organ or allogeneic HCT who have failed rituximab (± chemotherapy for SOT) receive tabelecleucel, an allogeneic, off‑the‑shelf EBV‑specific cytotoxic T‑cell therapy matched by HLA and infused on days 1, 8, and 15 of 35‑day cycles. Excludes T‑cell lymphomas, active/untreated CNS PTLD, significant GVHD, recent checkpoint inhibitors or EBV‑directed cell therapies, and requires measurable FDG‑avid disease and adequate organ function.

ClinicalTrials.gov ID: NCT03394365

A Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naïve, Metastatic Pancreatic Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Treatment-naïve adults with metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receive modified FOLFIRINOX plus nivolumab with NC410, a recombinant LAIR-2–IgG1 Fc fusion protein that binds tumor collagen to block LAIR-1 inhibitory signaling and enhance T-cell activity; a second cohort adds ipilimumab. Excludes prior ICI/PDAC therapy and significant autoimmune/immunosuppression, with efficacy and safety endpoints including ORR, PFS, and toxicity.

ClinicalTrials.gov ID: NCT06941857

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Previously untreated adults with metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) are randomized to gemcitabine/nab-paclitaxel plus SBP-101 (ivospemin) versus placebo; SBP-101 is a polyamine analogue that modulates polyamine metabolism (inhibits ODC1 and S-adenosylmethionine decarboxylase) with preferential pancreatic uptake. Key exclusions include prior systemic therapy for metastasis, BRCA1/2 mutation if known, metformin use, retinopathy risk, active infections, and significant cardiopulmonary comorbidity.

ClinicalTrials.gov ID: NCT05254171

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic pancreatic adenocarcinoma progressing on gemcitabine (ECOG 0–1, limited comorbidities, adequate organ function) are randomized to glufosfamide 4500 mg/m2 IV q21d versus weekly bolus 5‑FU. Glufosfamide is an investigational oxazaphosphorine alkylating prodrug linked to glucose to enhance tumor uptake via GLUTs, releasing isophosphoramide mustard to form DNA crosslinks; key risks include renal tubular toxicity and myelosuppression.

ClinicalTrials.gov ID: NCT01954992

A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, unresectable or metastatic pancreatic ductal adenocarcinoma (ECOG 0–1, RECIST-measurable) are randomized to mFOLFIRINOX with or without OT-101, an intravenous antisense oligonucleotide that downregulates TGF-β2 to counter tumor immune evasion and metastasis. Primary endpoint is overall survival, with key secondary endpoints of PFS and ORR.

ClinicalTrials.gov ID: NCT06079346

IGNITE: A Phase 2 Study of Maintenance Combinatorial Myeloid Immunotherapy in Patients With Unresectable Pancreatic Ductal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable PDAC (metastatic or locally advanced) who have completed 16–24 weeks of first-line chemotherapy with no progression (stable disease or partial response), ECOG 0–1, measurable disease, and willingness for paired tumor biopsies. Patients receive maintenance IV odetiglucan (soluble β-glucan innate/myeloid immune activator engaging complement/CR3 pathways) plus IV mitazalimab (agonistic anti-CD40 antibody to activate APCs and promote T-cell priming/macrophage reprogramming), with primary efficacy focused on metastatic patients with partial response after induction chemotherapy.

ClinicalTrials.gov ID: NCT07199764

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling fit adults (ECOG 0–1) with previously untreated KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma. Patients are randomized to first-line mFOLFIRINOX or NALIRIFOX plus setidegrasib/ASP3082, an IV KRAS G12D-targeted protein degrader, versus placebo plus the same chemotherapy backbone.

ClinicalTrials.gov ID: NCT07409272

A Phase I/IIa Randomized Clinical Trial to Evaluate the Efficacy of EGFR-targeted, PNU-159682-packaged Nanocells & Glycolipid-Packaged Nanocells in Combination With Gemcitabine & Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with EGFR-expressing metastatic pancreatic ductal adenocarcinoma, ECOG 0–1, with measurable disease and progression on first-line 5‑FU–based irinotecan/oxaliplatin therapy (FOLFIRINOX or NALIRIFOX) and no more than one prior metastatic line. Randomized 2:1 to gemcitabine/nab-paclitaxel plus investigational EDV nanocells (EGFR-targeted nanocell delivering the cytotoxic payload PNU-159682 plus a non-targeted α-galactosylceramide–loaded nanocell to activate iNKT-cell immune responses) versus gemcitabine/nab-paclitaxel plus placebo.

ClinicalTrials.gov ID: NCT07049055

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial evaluates MDNA11, an IL-2 Superkine targeting the IL-2 beta receptor to enhance anti-tumor immunity, administered alone or with pembrolizumab, in adult patients with locally advanced or metastatic solid tumors. Eligible patients must have an ECOG performance status of 0 or 1 and adequate organ function.

ClinicalTrials.gov ID: NCT05086692

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with advanced or metastatic gastric/GEJ adenocarcinoma, NSCLC, or pancreatic ductal adenocarcinoma expressing CEACAM5, who have progressed after 1–3 prior systemic therapies. The trial investigates M9140, an antibody-drug conjugate targeting CEACAM5 and delivering a topoisomerase I inhibitor payload, as monotherapy in these populations.

ClinicalTrials.gov ID: NCT06710132